Moderate

Hodgkin lymphoma - management

Hodgkin · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A curable lymphoma characterised by Reed-Sternberg cells, typically presenting with painless lymphadenopathy and sometimes B symptoms. Stage-adapted, response-adapted chemotherapy (with or without radiotherapy) achieves high cure rates.

Red flags

  • SVC obstruction from mediastinal mass
  • Airway compromise
  • Spinal cord compression
  • Rapidly progressive bulky disease
  • Severe B symptoms with deterioration

Assessment

Differential diagnosis

  • Non-Hodgkin lymphoma
  • Reactive lymphadenopathy / infection
  • Sarcoidosis
  • Metastatic carcinoma
  • Tuberculosis
  • Nodular lymphocyte-predominant Hodgkin lymphoma

Investigations

  • Excisional lymph node biopsy (core often insufficient)
  • FBC, ESR, LDH, LFTs, renal function
  • HIV, hepatitis B/C serology
  • PET-CT for staging and interim response
  • Bone marrow (often replaced by PET)
  • Echocardiogram and lung function before anthracycline/bleomycin

Management

  • Confirm diagnosis by excisional biopsy with expert haematopathology
  • Stage with PET-CT (Ann Arbor / Lugano) and identify B symptoms and bulk
  • Assess cardiac and pulmonary fitness and fertility preservation before therapy
  • Treat early-stage favourable disease with short combined chemotherapy +/- involved-site radiotherapy
  • Treat advanced-stage disease with multi-agent chemotherapy (ABVD or escalated regimens / brentuximab-AVD)
  • Use interim PET to adapt therapy - de-escalate or intensify by response
  • Omit or modify bleomycin based on PET response and lung toxicity risk
  • Manage relapsed/refractory disease with salvage chemotherapy and autologous transplant
  • Use brentuximab vedotin and checkpoint inhibitors (nivolumab/pembrolizumab) in relapse
  • Provide survivorship care for late cardiac, pulmonary and second-malignancy risks

Drugs & doses

ABVD: doxorubicin 25 mg/m2 + bleomycin 10 units/m2 + vinblastine 6 mg/m2 + dacarbazine 375 mg/m2 IV days 1 & 15 per cycle
Brentuximab vedotin-AVD for advanced disease (replaces bleomycin)
Pembrolizumab or nivolumab for relapsed/refractory disease
Antiemetics and growth factor support as needed

Disposition

Haematology/oncology outpatient-led therapy; urgent admission for mass-effect emergencies; long-term survivorship follow-up.

Complications & pitfalls

  • Bleomycin lung toxicity
  • Anthracycline cardiotoxicity
  • Infertility
  • Secondary malignancies (breast, lung, leukaemia)
  • Relapse

Exam pearls

  • Hodgkin lymphoma is highly curable even at advanced stage
  • Interim PET enables response-adapted therapy to limit toxicity
  • Excisional biopsy is preferred for diagnosis
  • Discuss fertility preservation before starting treatment
  • Long-term survivorship surveillance for cardiac disease and second cancers is essential

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.